<DOC>
	<DOCNO>NCT01623310</DOCNO>
	<brief_summary>This open-label , multicenter study design ass safety intranasal administration 400 μg fluticasone propionate twice day deliver OptiNose device subject chronic sinusitis without nasal polyp . The study consist up-to-7-day pretreatment phase follow 12-month open-label treatment phase . The duration subject 's participation approximately 53 week .</brief_summary>
	<brief_title>12-Month OL Safety Study Intranasal 400 μg Fluticasone Propionate BID Using Novel Bi-Directional Device CS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Men woman age 18 year old Women must practice effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , doublebarrier method [ eg , condom , diaphragm , cervical cap spermicidal foam , cream , gel ] , male partner sterilization ) entry throughout study , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation least 1 year screen ) otherwise incapable pregnancy , postmenopausal ( spontaneous amenorrhea least 1 year ) . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( βhCG ) pregnancy test screen visit Have either : history chronic sinusitis bilateral nasal polyposis determine nasoendoscopy screen visit OR history chronic sinusitis ( without polyp ) equal great 12 week currently experience 2 follow symptom , one MUST either nasal blockage/congestion nasal discharge ( anterior and/or posterior nasal discharge ) : 1. nasal blockage/congestion 2. nasal discharge ( anterior and/or posterior nasal discharge ) 3. facial pain pressure 4. reduction loss smell Subjects comorbid asthma COPD must stable exacerbation ( eg , emergency room visit , hospitalization , oral parenteral steroid use ) within 3 month screen visit . Inhaled corticosteroid use must limit stable dos 1,000 μg/day beclomethasone ( equivalent ; See Attachment 1 ) least 3 month screen plan continue use throughout study . Must able cease treatment intranasal steroid inhale corticosteroid ( except permit dos list asthma COPD ) screen visit Must able use OptiNose device correctly ; subject require demonstrate correct use placebo device screen visit , see Section 12.1 , Visit 1 , screen procedure . Must capable , opinion investigator , provide informed consent participate study . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . Women pregnant lactate Inability nasal cavity examine reason , include nasal septum deviation Nasal septum perforation Has 1 episode epistaxis frank bleed month screen visit Have evidence significant baseline mucosal injury , ulceration erosion ( eg , exposed cartilage , perforation ) baseline nasal examination/nasoendoscopy History sinus nasal surgery within 6 month screen visit Current , ongoing rhinitis medicamentosa ( rebound rhinitis ) Have significant oral structural abnormality , eg , cleft palate Diagnosis cystic fibrosis History ChurgStrauss syndrome dyskinetic ciliary syndrome Purulent nasal infection , acute sinusitis , upper respiratory tract infection within 2 week screen visit . Potential subject present infection may rescreened 4 week symptom resolution Planned sinonasal surgery period study Allergy , hypersensitivity , contraindication corticosteroid steroid Allergy hypersensitivity excipients study drug Exposure glucocorticoid treatment potential systemic effect ( eg , oral , parenteral , intraarticular , epidural steroid , high dose topical steroid ) within 1 month screen visit ; except note inclusion criterion subject comorbid asthma COPD Have nasal candidiasis Have take potent CYP3A4 inhibitor within 14 day screen visit ; example medication find Section 11.6 , Concomitant Medication . History current diagnosis form glaucoma ocular hypertension ( ie , intraocular pressure &gt; 21 mmHg ) History intraocular pressure elevation form steroid therapy History current diagnosis presence ( either eye ) cataract Any serious unstable concurrent disease , psychiatric disorder , significant condition , opinion investigator could confound result study could interfere subject 's participation compliance study A recent ( within 1 year screen visit ) clinically significant history drug alcohol use , abuse , dependence , opinion investigator could interfere subject 's participation compliance study Positive urine drug screen screen visit drug abuse ( see Section 14.5 ) , exception prescribe medication legitimate medical condition Have participate previous clinical trial OPTINOSE FLUTICASONE Have participate investigational drug clinical trial within 30 day screen visit Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>